Cerebrospinal fluid (CSF) levels of tau proteins, ɑ-synuclein, and β-amyloid 1-42 (Αβ1-42) appear to be associated with early stage Parkinson disease (PD) in a group of untreated patients compared with healthy patients, according to a study by Ju-Hee Kang, M.D., of the University of Pennsylvania, and colleagues.
The study included the initial 102 research volunteers (63 patients with PD and 39 healthy control patients) of the Parkinson's Progression Markers Initiative (PPMI) study.
Results indicate that slightly, but significantly, lower levels of Αβ1-42, T-tau, P-tau181, ɑ-synuclein and T-tau/Αβ1-42 were seen in patients with PD compared with healthy control patients. Lower Αβ1-42 and P-tau181 levels were associated with PD diagnosis, and decreased CSF T-tau and ɑ-synuclein levels were associated with increased motor severity, the results also show.
"In this first report of CSF biomarkers in PPMI study subjects, we found that measures of CSF Αβ1-42, T-tau, P-tau181 and ɑ-synuclein have prognostic and diagnostic potential in early-stage PD. Further investigations using the entire PPMI cohort will test the predictive performance of CSF biomarkers for PD progression," the study concludes.
(JAMA Neurol. Published online August 26, 2013. doi:10.1001/.jamaneurol.2013.3861. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor's Note: Numerous conflict of interest and funding disclosures were made. Please see the articles for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.